2024-11-0920171064-196310.1080/10641963.2016.12465652-s2.0-85018312749http://dx.doi.org/10.1080/10641963.2016.1246565https://hdl.handle.net/20.500.14288/12341Organ crosstalk pathways represent the next frontier for target-mining in molecular medicine for existing syndromes. Pulmonary hypertension and resistant essential hypertension are syndromes that have been proven elusive in etiology, and frequently refractory to first-line management. Underlying crosstalk mechanisms, not yet considered in these treatments, may hinder outcomes or unlock novel treatments. This review focuses systematically on erythropoietin, a synthesizable molecule, as a mediator of brain-kidney crosstalk. Insights gained from this review will be applied to cardiovascular diseases in a clinician-directed fashion.PharmacologyPharmacyPeripheral vascular diseaseReview1525-6006400341300001Q14061